SCHEMBL20468950

SCHEMBL20468950

Cc1cnc(N2CCC3(CCN(C(=O)OC(C)(C)C)C3)C2)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 5/20 0.52
▸ CYP11B2 P19099 1/20 0.50
▸ OGA O60502 1/20 0.48
▸ SCD5 Q86SK9 1/20 0.46
▸ TSHR P16473 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ RET P07949 6/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SPR P35270 2/20 0.43
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20468951 0.85 CYP11B2 (0.53) ACACBCYP11B2SCD5TSHRHSD17B10
SCHEMBL20469060 0.83 ACACB (0.50) ACACBCYP11B2SCD5TSHRHSD17B10
SCHEMBL20469058 0.83 CYP11B2 (0.53) ACACBCYP11B2SCD5TSHRHSD17B10
SCHEMBL20468941 0.82 CYP11B2 (0.49) ACACBCYP11B2SCD5TSHRHSD17B10
SCHEMBL20468960 0.81 CYP11B2 (0.56) ACACBCYP11B2SCD5TSHRRET
SCHEMBL20468957 0.81 ACACB (0.52) ACACBCYP11B2SCD5TSHRHSD17B10
SCHEMBL20468948 0.81 CYP11B2 (0.53) ACACBCYP11B2SCD5TSHRHSD17B10
SCHEMBL2366741 0.81 RET (0.50) TSHRRETALDH1A1
SCHEMBL20468943 0.80 CYP11B2 (0.53) ACACBCYP11B2OGASCD5TSHR
SCHEMBL20468945 0.80 ACACB (0.52) ACACBCYP11B2SCD5TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048267-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2020-02-13 — — US disclosed
WO-2018141984-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048267-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN ACACB 639/4885CYP11B2 4635/4885OGA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback